Ambrisentan | 合法藥品大搜索

2020年11月20日—Ambrisentanisanoralmedicationclassifiedasanendothelinreceptorantagonist(ERA)whichisapprovedforthetreatmentofpulmonary ...

Ambrisentan treats pulmonary arterial hypertension (PAH), also known as Group 1 pulmonary hypertension. This medication aims to improve exercise ability and slow progression of the disease.

The Food and Drug Administration (FDA) approved Letairis in 2007 to treat PAH. Letairis also is available as a generic drug, ambrisentan.

How ambrisentan worksAmbrisentan is an endothelin receptor antagonist. It works by blocking endothelin, a substance made by the body that causes the blood vessels in the arteries of the lungs to constrict. Endothelin causes abnormal growth of the muscular layer in the vessel wall, which narrows the lumen, or space inside the blood vessel.

This narrowing causes the pressure to increase, making it harder for the right side of the heart to push the blood through the lungs to get oxygen. By blocking the action of endothelin, ambrisentan helps relax the blood vessels so the lung blood pressure goes down. Lower lung pressures reduce stress on the...